- Conditions
- Alzheimer Disease
- Interventions
- ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1897–1920
of 2,415
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Wheezing, Reactive Airway Disease, Mild Asthma
- Interventions
- VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
- Combination Product
- Lead sponsor
- Vectura Limited
- Industry
- Eligibility
- 4 Years to 8 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Colorado Springs, Colorado • Raleigh, North Carolina • Tulsa, Oklahoma
- Conditions
- Cerebrovascular Disease, Mild Cognitive Impairment
- Interventions
- Heart Health Intervention
- Behavioral
- Lead sponsor
- Gregory Jicha, 323-5550
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Mild Cognitive Impairment
- Interventions
- Aerobic & Cognitive Training (ACT), Cycling Only, Cognitive Training Only, Stretching and Mental Stimulating Activities
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Stanford, California • Minneapolis, Minnesota + 1 more
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
- Interventions
- Risk Assessment Cognitive Screening
- Diagnostic Test
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hepatic Impairment
- Interventions
- BG9928
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Crohn's Disease
- Interventions
- Serum-derived Bovine Immunoglobulin / Protein Isolate, Placebo
- Other
- Lead sponsor
- Entera Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 7
- States / cities
- North Little Rock, Arkansas • Hollywood, Florida • Winter Park, Florida + 3 more
- Conditions
- Mild Cognitive Impairment
- Interventions
- active supplement, placebo
- Dietary Supplement · Other
- Lead sponsor
- University of Georgia
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Athens, Georgia
- Conditions
- Concussion, Mild, TBI (Traumatic Brain Injury), Mild Traumatic Brain Injury
- Interventions
- Not listed
- Lead sponsor
- ElMindA Ltd
- Industry
- Eligibility
- 15 Years to 50 Years
- Enrollment
- 46 participants
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Math Learning Disability, Child Development, Developmental Disability, Learning Disabilities, Learning Disabled, Learning Curve, Mathematics Disorder, Dyscalculia, Dyscalculia, Primary, Dyscalculia, Acquired, Specific Learning Disorder, With Impairment in Mathematics, Individuality, Behavior, Child, Behavior and Behavior Mechanisms, Behavior, Decision Making, Neuronal Plasticity, Cognition, Cognition Disorder, Cognitive Dysfunction, Cognitive Change, Cognitive Impairment, Mild, Cognitive Developmental Delay, Cognitive Orientation, Cognitive Delay, Mild, Cognitive Deficits, Mild, Cognitive Abnormality, Neuroscience
- Interventions
- Interventions in Mathematics and Cognitive Skills - Experimental, Interventions in Mathematics and Cognitive Skills - Active Comparator
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Mild Cognitive Impairment, Mild Alzheimer's Disease
- Interventions
- AZD5213, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Indio, California • Lomita, California + 10 more
- Conditions
- Mild Cognitive Impairment
- Interventions
- External Counterpulsation (EECP)
- Device
- Lead sponsor
- Patrick Moriarty, MD, FACP, FACC
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
- Interventions
- NBI-98854 50 mg capsule
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Concussion, Brain, Concussion, Mild, Concussion
- Interventions
- BCAA, Placebo
- Drug · Other
- Lead sponsor
- Akiva Cohen
- Other
- Eligibility
- 11 Years to 23 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Digestive, Gastrointestinal Health
- Interventions
- Enzyme Cocktail A, Enzyme Cocktail B, Placebo A, Placebo B
- Dietary Supplement
- Lead sponsor
- The Archer-Daniels-Midland Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Denton, Texas
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Data-Driven Clinical Recommendations, Coached Data-Driven Clinical Recommendations
- Behavioral
- Lead sponsor
- Saint John's Cancer Institute
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Alzheimer's Disease
- Interventions
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment
- Interventions
- 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company), 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Alzheimer Disease
- Interventions
- CT1812, Placebo
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- PostPartum Depression
- Interventions
- MamaLift Plus, Digital Sham App
- Device
- Lead sponsor
- Healthcare Innovation Technology Lab
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Mild or Moderate Surgical Bleeding
- Interventions
- Fibrocaps, Gelatin sponge
- Biological
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 721 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Nanocrystalline silver cream (NPI)
- Drug
- Lead sponsor
- Nucryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Denver, Colorado + 15 more
- Conditions
- Alzheimer's Disease
- Interventions
- Albumin 5%, Albumin 20%, Immunoglobulin
- Biological
- Lead sponsor
- Instituto Grifols, S.A.
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 22
- States / cities
- Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Interventions
- Donanemab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 42
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Carlsbad, California + 36 more